Skip to main content

Latest News

Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease

May 12, 2016

Diversity by Design

Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases.


Product Pipeline

SER-109, our lead development candidate for the prevention of Clostridium difficile infection, has been designated by the FDA as a Breakthrough Therapy.


Clinical Trials

The ECOSPORTM Phase 2 clinical study is focused on the safety and efficacy of our Ecobiotic® drug, SER-109, an investigational microbiome therapeutic orally delivered as a capsule.


Back to top